What is inclusion body myositis?

Inclusion Body Myositis (IBM) is a rare, progressive muscle disease characterized by chronic muscle inflammation and weakness. It is the most common acquired muscle disease in adults over 50, affecting approximately 20,000 people in the United States.

Sporadic IBM (sIBM), the most common form, is NOT inherited — it occurs randomly. However, about 67% of patients carry a specific HLA gene combination that makes them genetically susceptible. Hereditary Inclusion Body Myopathies (hIBM) are a separate group of genetic muscle diseases.

Is there a cure for IBM?

As of 2026, there are no FDA-approved treatments specifically for IBM. The disease is notoriously resistant to corticosteroids and immunosuppressive drugs. Physical therapy and adaptive strategies are the mainstay of management. Active research is underway with promising clinical trials.

Does IBM qualify for disability benefits?

Yes. IBM is listed under Section 11.15 (Disorders of the Peripheral Nervous System) in the SSA Blue Book for Social Security Disability Insurance (SSDI). The IBM Functional Rating Scale can support your application.

What exercises are safe with IBM?

Walking, aquatic therapy, light resistance training, balance training, and hand/finger exercises are all recommended for IBM patients. Start slowly, build over 6-12 weeks, and consult with a physical therapist who understands myositis.

Why is IBM often misdiagnosed?

IBM is frequently misdiagnosed as polymyositis, normal aging, fibromyalgia, ALS, or sarcopenia. The average diagnostic delay is 5-10 years from symptom onset because IBM shares symptoms with more common conditions.

IBM Patients Face 2.5x Higher Fall Risk — And a New Tool Is Being Built to Track It

Two new peer-reviewed studies published in June 2026 shed light on issues every IBM patient and caregiver should know about: how dangerous falls really are, and how researchers are building better tools to measure what IBM does to your daily life.

IBM Has the Highest Fall Risk of Any Inflammatory Myopathy

A cross-sectional study published in Rheumatology and Therapy surveyed 470 patients with idiopathic inflammatory myopathies (IIMs) — including dermatomyositis, polymyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, and IBM. The results were striking:

• 79.8% of patients had fallen at least once since diagnosis

• 57.0% had fallen within the past year

• 25.7% experienced fall-related fractures

• Of those who fractured, 50.4% had multiple fractures and 32.2% required surgery

Most concerning for IBM patients: compared to dermatomyositis, IBM patients had a 2.5 times higher odds of falling. Polymyositis patients also had elevated risk (2.0x). Antisynthetase syndrome patients had lower risk (0.5x).

The study also found a troubling gap in care: nearly half (47.9%) of patients who fractured were not taking any bone-protective therapy — no calcium, no vitamin D, no bisphosphonates. This represents a major missed opportunity for secondary fracture prevention.

Mobility aid use was reported by 77.7% of patients with fractures, and using a mobility aid was itself associated with higher fall risk (3.1x) — a reflection of the severity of underlying weakness rather than the aids causing falls.

What you can do: Talk to your doctor about a bone density scan and whether calcium, vitamin D, or bisphosphonates are appropriate for you. Fall prevention — grab bars, non-slip flooring, balance training — isn't optional with IBM. It's essential.

A New Tool to Measure What IBM Actually Feels Like

A separate study published in the Journal of Clinical Neuromuscular Disease describes the development and validation of the IBM-Health Index (IBM-HI) — a new patient-reported outcome measure designed specifically for IBM clinical trials.

The IBM-HI was built from the ground up by surveying 569 IBM patients about the symptoms that most impact their daily lives. The researchers then validated the instrument through factor analysis, beta testing, test-retest reliability, and known groups analysis.

Key findings:

• The IBM-HI has 13 subscales covering the full spectrum of IBM symptoms

• Test-retest reliability was excellent (intraclass correlation coefficient = 0.95)

• The tool can differentiate between patients with different levels of disability, ambulation status, and disease duration

• Patients found it easy to use and highly relevant to their condition

Why this matters: As new treatments move toward clinical trials, researchers need reliable tools to measure whether a drug actually helps patients feel and function better. The IBM-HI provides exactly that — a regulatory-grade instrument that captures the patient's perspective, not just lab values or muscle strength tests.

This is infrastructure work that doesn't make headlines, but it's what enables the next generation of IBM treatments to be properly tested and, if effective, approved.

Sources

• Nandakumar D, et al. "Prevalence and Risk of Falls and Fractures in the Idiopathic Inflammatory Myopathies." Rheumatology and Therapy. 2026;13(3):677-689. https://link.springer.com/article/10.1007/s40744-026-00829-2

• Irwin C, et al. "Development and Validation of the Inclusion Body Myositis-Health Index." Journal of Clinical Neuromuscular Disease. 2026;27(4):124-139. https://doi.org/10.1097/CND.0000000000000564

IBM Patients Face 2.5x Higher Fall Risk — And a New Tool Is Being Built to Track It

IBM Has the Highest Fall Risk of Any Inflammatory Myopathy

A New Tool to Measure What IBM Actually Feels Like

Key findings:

Sources

Tags

Related Reading

More Research